Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

OBJECTIVE: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-β. However, whether such an improvement was translated into cost savings remained unclear. We therefor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-de la Rosa, Rainel, García-Bujalance, Laura, Meca-Lallana, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608957/
https://www.ncbi.nlm.nih.gov/pubmed/26475277
http://dx.doi.org/10.1186/s13561-015-0066-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608957/
https://www.ncbi.nlm.nih.gov/pubmed/26475277
http://dx.doi.org/10.1186/s13561-015-0066-2

Ejemplares similares